You are here:     > Corporate Overview >Bringing Quality Medicines to Patients all over the World

Bringing Quality Medicines to Patients all over the World

Over the last decade, Glenmark has evolved into a global organisation. Whether it is the developed markets of the US and Europe or emerging economies in Asia, Africa and Latin America, Glenmark’s quality medicines reach patients in need all over the world with a robust portfolio of hundreds of products.

More than 70% of our revenue is generated outside India. This international scaling up of our business has been underpinned by a strong focus on affordability and quality. We have invested in efficient product development and manufacture to make our offerings available at affordable prices. We have also implemented measures to shape an organisation-wide culture of quality focused on high levels of compliance. Together, these steps have allowed us to maximise the number of patients who benefit from our cost-effective products and ensured that we consistently provide them with high-quality medicines wherever in the world they may live.

Improving Access

We are bringing high-quality medicines, manufactured in facilities approved by some of the world’s most stringent regulators, within reach of millions all over the world at affordable prices. For instance, in the US generics market where we have a significant presence, the average price of a brand Rx product is USD 765, almost 27 times the average price of a generic Rx product at USD 271. By making generics of a range of high-priced branded drugs available, we are daily contributing to lowering healthcare costs for the consumers and payers.

Generic manufacturers retain just 36% or USD 9.86 of the average price per generic Rx compared with brand companies that retain 76% or USD 574.56 of the far higher average price per brand Rx1. In spite of this relatively lower average realisation, Glenmark’s generics business has grown strongly backed by a robust and efficient manufacturing and supply chain. We are now the 14th largest generics manufacturer by prescription2 and our US FDA approved products are used to fill about 83 Mn scrips each year in the US. Almost three prescriptions are filled by Glenmark products every second and one in four Americans consumes a Glenmark product.

A Member of Glenmark's Manufacturing Team

In India, we have established ourselves as a leading company and a recognised and respected brand with revenues growing at a fast clip. Our products are stocked in over 50,000 pharmacies. With this reach and the breadth of

In the US, where the
average price of a brand
Rx drug is 27 times
that of a generic, our
range of high-quality
generic drugs
is daily
contributing to lowering
healthcare costs
for
patients and payers


1 IQVIA and USC Scheaffer Study
2 IQVIA Health



our portfolio in both products and dosage forms, we have achieved strong market positions in our key focus areas. According to IQVIA data, we are ranked second in Dermatology, fourth in Respiratory, sixth in Cardiac and 15th in the Diabetes segment.

Our reach also extends to underserved markets — or pockets within markets — with an approach devised to improve access. In the African region, which has countries with the fewest number of doctors and poor health indicators, we are present in 20 countries with products in a range of therapy areas. Our outreach initiatives include conducting spirometry camps for asthma detection, blood pressure monitoring camps and patient education initiatives such as helping pregnant women understand the importance of nutrition.

In Russia, we are among the leaders in the cough syrup market and have a strong presence in dermatology. In Kenya, Glenmark is ranked seventh in that country’s pharma industry, while in South Africa, we are a Top 50 Company. In Latin America, we are present in 12 countries with a portfolio of over 280 products.

With 16 factories across four continents, our manufacturing footprint has also grown to support our ever-expanding global presence. We make over 20 dosage forms and over 6,000 stock keeping units or SKUs.



1 in 4 Americans

consumes a Glenmark
product


Maps are not drawn to scale and are for
visual representation only

A Member of Glenmark's Manufacturing Team



Focus on Quality

At Glenmark, quality is not just tested. It is built into everything we do. Whether it is drug development, manufacturing, distribution or post-market surveillance, we have integrated quality into every process that has an impact on the end product.

Drug development is the first step in the journey towards commercialisation. We are acutely conscious that a quality flaw at this stage, however minor, will At the manufacturing stage, our facilities follow standard operating procedures and our systems and processes are continuously evaluated through periodic audits. To ensure defect-free output, every product goes through an average of 120 tests from raw material to finished product stage. Our manufacturing facilities are in compliance mode at all times carry forward and could escalate into a serious problem with the end product. At Glenmark, we use ‘Quality by Design’ principles to design a pure, safe and effective product. Our team develops robust commercial processes to ensure that quality product is consistently produced in our factories. We have established product specifications and standard testing procedures to ensure rigorous quality control. On average, each Glenmark product is put through 2,000 to 2,500 tests even before commercialisation.

On average, each
Glenmark product is
put through 2,000 to
2,500 tests even before
commercialisation



At the manufacturing stage, our facilities follow standard operating procedures and our systems and processes are continuously evaluated through periodic audits. To ensure defect-free output, every product goes through an average of 120 tests from raw material to finished product stage. Our manufacturing facilities are in compliance mode at all times to ensure the supply of safe and effective medicines to patients. We undergo an average of one regulatory inspection every three days. Our 16 manufacturing facilities cumulatively adhere to the regulatory requirements of over 35 separate health authorities. Nine of these, across four continents, are approved by the US FDA.

Our 16 manufacturing facilities cumulatively adhere to the regulatory requirements of over 35 separate health authorities



We are aware that reliable supply is the hallmark of a quality organisation. Our Top 20 finished dosage products have multi-site approvals to mitigate supply chain disruptions. Our sourcing partners are picked for their ability to ensure on-time product delivery and stable supply.

We continue to own full responsibility for our products even after they leave the factory gates. Our products are shipped with data loggers that help us track whether or not they were maintained in the appropriate conditions. Our distribution centres comply with good warehousing practices.

The patient is our ultimate customer and a facilitator of our endeavour to stay high quality at all times. Our global clearing house project collates feedback from patients all over the world and channels it to the organisation. This feedback system is an important pathway to improvement in our products, processes, SOPs, etc. Customer feedback is also vital to enable emergency actions such as field alerts or product recalls.

The results speak for themselves. While the volumes manufactured at our facilities have substantially increased year-on-year from over 6,500 batches in 2013 to over 16,000 batches currently, our complaints rate is less than 0.14 per Mn units, a significant improvement over Six Sigma, which is 3.4 defects per Mn units. Our patients, wherever in the world they may be, have grown to expect high quality, dependability, and responsiveness from Glenmark. Each day, we strive to retain and cement this reputation, built over several decades, and in multiple markets.

Glenmark’s Manufacturing Facility in Monroe, North Carolina, USA

A Member of Glenmark’s Manufacturing Team